drugset
drugset / Trial / NCT04668118

The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye

NCT04668118 ↗

Phase 4 Unknown 68 enrolled Peking University Third Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of 3% Diquafosol Ophthalmic Solution for visual display terminal (VDT)-associated dry eye and to investigate the mechanism of treatment.

Timeline

Start
2021-02-01
Primary completion
2022-10-01
Completion
2023-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Diquafosol Oligonucleotide (other) 3 % —

Indications

VISS syndrome asthenopia dry eye syndrome